Related Experiment Video
Updated: Jul 12, 2026
09:58
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
Published on: December 9, 2016
DRIVE: a comprehensive resource deciphering drug-induced transcriptomic and splicing response in cancer cell
Tao Wu1, Hong-Feng Tang2, Wei-Liang Wang3
1Department of Dermatology, Yangjiang People's Hospital affiliated to Guangdong Medical University, Yangjiang, Guangdong, China; The Eighth Affiliated Hospital, Southern Medical University (The First People's Hospital of Shunde), Foshan, Guangdong, China.
Neoplasia (New York, N.Y.)
|July 10, 2026
Summary
The DRIVE database offers a comprehensive resource on drug-induced cancer cell changes, revealing context-dependent responses and identifying potential immunomodulatory drugs and splicing modulators for combination immunotherapy.
Area of Science:
- Oncology
- Computational Biology
- Pharmacology
Background:
- Pharmacotherapy causes significant molecular changes in cancer, including altered gene expression and alternative splicing.
- Existing resources lack comprehensive data on drug-induced transcriptomic and splicing alterations, hindering neoantigen landscape analysis.
- Aberrant splicing can create neoantigens, but integrating drug effects with splicing and neoantigen data is limited.
Purpose of the Study:
- To create the DRIVE database, a resource detailing drug-induced transcriptomic and splicing responses in cancer.
- To systematically analyze drug perturbations, splicing dynamics, and neoantigen generation.
- To provide a platform for understanding drug mechanisms and discovering novel therapeutic strategies.
Main Methods:
- Processed thousands of public transcriptomic datasets from drug-treated and control cancer cell lines.
- Utilized large language models for metadata curation and a standardized processing pipeline.
- Quantified differential gene expression, alternative splicing events, and predicted HLA-binding peptides.
Main Results:
- The DRIVE database contains 3,911 samples across 278 drugs and 272 cell lines.
- Drug-induced transcriptomic reprogramming is context-dependent and correlates with chemical structure.
- Identified Osimertinib as a potential immunomodulator and KB-0742 as a splicing modulator.
- Predicted numerous drugs as candidates for combination immunotherapy based on neoantigen generation.
Conclusions:
- DRIVE enhances understanding of pharmacotherapy-induced molecular reprogramming in cancer.
- The database serves as a platform for deciphering drug mechanisms and drug repurposing.
- Identified specific drugs with potential for immunomodulation and combination immunotherapy.
Related Concept Videos
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:18Cancer
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.